Canadian well being regulators on Thursday authorized use of Novavax’s Nuvaxovid, a Covid vaccine made utilizing conventional protein-based expertise quite than newer mRNA strategies.
Nuvaxovid is the primary protein subunit Covid vaccine approved in Canada, which public well being consultants hope may persuade some who’re frightened of mRNA vaccines to get the jab.
In January, Canada agreed to buy 52 million doses of Nuvaxovid, with the choice to buy 24 million extra doses, Novavax introduced.
Nuvaxovid was 90.4% efficient at stopping Covid an infection and 100% efficient at stopping severe signs throughout medical trials, in line with a study printed December 15 within the New England Journal of Medication.
Trials confirmed few extreme unintended effects, the most typical reactions being headache, nausea, muscle ache and joint stiffness, Novavax stated.
Canada’s well being division, which cleared the vaccine for individuals aged 18 and up, recommended two doses be administered 21 days aside, although provinces and territories will decide sufferers’ vaccination schedules.
Whereas mRNA vaccines function by educating the cell to make a protein that stimulates immune response in opposition to a virus, protein subunit vaccines straight introduce innocent items of viral proteins to create an immune response. Although mRNA vaccines have been confirmed safe and effective, conspiracy theories declare that they’re inadequately examined, trigger infertility, alter DNA or promote Covid an infection. Due to this, it’s hoped that protein-based vaccines like Nuvaxovid will assist cut back vaccine hesitancy. Nuvaxovid has obtained conditional authorization from regulatory businesses together with the European Fee and the World Well being Group, and was submitted for U.S. Meals and Drug Administration authorization January 31. Novavax CEO Stanley Erck speculated that the FDA may authorize the vaccine in February, although the FDA stated it couldn’t foresee how lengthy it will take to finish an analysis. Novavax is contracted to ship about 2 billion doses of its vaccine worldwide, Erck stated in January.
80 million. That’s about how many individuals within the U.S. haven’t but obtained a single dose of Covid vaccine within the U.S., in line with the Facilities for Illness Management and Prevention.
“If Permitted, The Novavax Covid-19 Vaccine May Assist Cut back Vaccine Hesitancy In The U.S.” (Forbes)
“Novavax Asks FDA To Authorize Its Non-mRNA Covid Vaccine” (Forbes)